Profile to raise $40 million for smart inhaler:
This article was originally published in Clinica
Executive Summary
Profile Therapeutics plans to raise £25.5 million ($40 million) on the London Stock Exchange. The Bognor Regis, Sussex-based company is developing inhaled drug delivery systems, based around its Adaptive Aerosol Delivery technology, which produces reproducible and precise doses by adapting to patients' breathing patterns. The company, which began as an inhaler distributor in 1977, launched its first product, the HaloLite system, in 1998. Its present turnover is around £10 million and the flotation, due for March 31, values the company at £81 million.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.